Home・Stock List・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Closed

SectorHealthcare

27.59 3.41

Buy Sell

Overview

Share price change

24h

Current

Min

25.66

Max

26.9

Key metrics
By Trading Economics
Income	1.3M 2.9M
Sales	-19M 177M
P/E Sector Avg	203.615 64.641
EPS	0.6
Profit margin	1.644
Employees	825
EBITDA	5M 30M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+19.92% upside

Dividends
By Acuity
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-58M 1B
Previous open	24.18
Previous close	27.59

News Sentiment

By Acuity

21%

79%

38 / 340 Healthcare

Pacira Pharmaceuticals Inc-DE Chart

Past performance is not a reliable indicator of future results.

Related News

31 Jul 2026, 20:02 UTC

Pacira Biosciences Inc's shares are lower today, reaching a session low earlier. The price remains above its 20-day moving average despite the decline.

30 Jul 2026, 17:16 UTC

Pacira Biosciences is advancing during Thursday's session, regaining momentum after earlier pulling back from a session high amid broader market optimism.

29 Jul 2026, 20:04 UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a decline since Tuesday's close. The stock reached an early high before falling significantly.

28 Jul 2026, 19:56 UTC

Event

News

Shares of Pacira Biosciences Inc. are higher, driven by survey findings on orthopedic pain's impact on the workforce and strong interest in non-opioid treatments.

27 Jul 2026, 18:51 UTC

Event

News

Pacira Biosciences advances PCRX-201 to commercial manufacturing, allowing patient enrollment in Phase 2 ASCEND study. Shares are higher as investor confidence strengthens.

24 Jul 2026, 17:16 UTC

Pacira Biosciences Inc shares are lower today, with no specific news driving the decline. Broader market sentiment is impacted by falling crude oil prices.

22 Jul 2026, 18:06 UTC

Pacira Biosciences Inc shares are lower in Wednesday's session, pulling back from earlier gains amid broader market caution and rising crude oil prices.

21 Jul 2026, 19:56 UTC

Pacira Biosciences Inc is trading higher, reflecting broader market interest in technology and AI sectors ahead of upcoming earnings reports.

20 Jul 2026, 19:46 UTC

Pacira Biosciences Inc shares are trading lower today, having retraced from an earlier high. No specific news was identified to explain the decline.

Peer Comparison

Price change

Pacira Pharmaceuticals Inc-DE Forecast

Price Target

By TipRanks

19.92% upside

12 Months Forecast

Average 31.67 USD 19.92%

High 38 USD

Low 25 USD

Based on 3 Wall Street analysts offering 12 month price targets forPacira Pharmaceuticals Inc-DE - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Pacira Pharmaceuticals Inc-DE - Dist in the past 3 months.

Sentiment

By Acuity

38 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.